SAFIMESTOMIG
UNII LFQ9PP64F2
Substance Identification & Data
This profile provides standardized clinical and technical data for Safimestomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LFQ9PP64F2.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2911590-72-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
LFQ9PP64F2
2911590-72-0
N/A
Detailed Substance Profile
Preferred Name
SAFIMESTOMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13102
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Safimestomig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Safimestomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Safimestomig
Common Names & Synonyms
H-gamma4 heavy chain anti-CD47 humanized (1-451) [VH (Homo sapiens IGHV1-3*01 (85.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.17] (26-33.51-58.97-113)) (1-124)-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v6 CH3 K88, G4v11CH1 Q100, CH2 Y84.3, G4v12 CH3 K12, R115 (CH1 K100>Q (203) (125-222), hinge 1-12 S10>P (232) (223-234), CH2 F84.3>Y (300), L92 (313) (235-344), CH3 E12>K (360), R88>K (413), H115>R (439) (345-449), CHS (450-451)) (125-451)], (138-214')-disulfide with common L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-NL1*01 (88.4%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; H-gamma4 heavy chain anti-PD-L1 humanized (1''-446'') [VH (Homo sapiens IGHV1-69-2*01 (82.7%) -(IGHD) -IGHJ4*01 (92.9%) L123>T (114), CDR-IMGT [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'')-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v6 CH3 K88, G4v11 CH1 Q100, CH2 Y84.3, G4v13 CH3 E119 (CH1 K100>Q (198'') (120''-217''), hinge 1-12 S10>P (227'') (218''-229''), CH2 F84.3>Y (295''), L92 (308'') (230''-339''), CH3 R88>K (408''), K119>E (438'') (340''-444''), CHS (445''-446'')) (120''-446'')], (133''-214''')-disulfide with common L-kappa light chain humanized (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-NL1*01 (88.4%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'''-32'''.50'''-52'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'''), V101 (191''')) (108'''-214''')]; dimer (230-225'':233-228'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa
Immunoglobulin G4 [232-proline,360-lysine,439-arginine], bispecific, anti-(human CD47 antigen) (human-Mus musculus monoclonal 6MW3211 γ4-chain), (230→228′),(233→225′)-bis(disulfide) with immunoglobulin G4 [227-proline,438-glutamic acid] anti-(human programmed death-ligand PD-L1) (human-Mus musculus monoclonal 6MW3211 γ4-chain), disulfide with human-Mus musculus monoclonal 6MW3211 κ-chain
immunoglobulin G4-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3)] and anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, PDCD1LG1)], humanized monoclonal antibody, bispecific, bivalent
safimestomig [INN]
Technical Codes
6MW3211
